Intercept initiated with a Neutral at Goldman Goldman Sachs started shares of Intercept with a Neutral rating saying it's difficult to value the company's obeticholic acid for the treatment of nonalcoholic steatohepatitis without the FLINT trial data, which is due out later this year. Goldman put a $265 price target on the stock.
News For ICPT From The Last 14 Days
Check below for free stories on ICPT the last two weeks.
Intercept started with Underperform, $172 target at FBR Capital FBR Capital initiated shares of Intercept with an Underperform rating and $172 price target. The stock closed yesterday at $296.36. FBR believes investors are too optimistic on the nonalcoholic steatohepatitis market and the company's path to commercialization for its obeticholic acid. The firm thinks Intercept may face payor pushback and restriction as its drug will be competing with hepatitis C treatments for dollars.